Paclitaxel poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer (NSCLC) in Women with Estradiol > 30 pg/ml To compare the overall survival of patients randomized to the CT-2103/carboplatin arm to that of patients randomised to the comparator arm (paclitaxel/carboplatin).

• Country None
• organs None
• Specialty None

Paclitaxel Poliglumex (CT-2103) vs Paclitaxel for the Treatment of Women with Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) who are Performance Status 2 The primary objective of this study is to compare the overall survival of female patients randomized to CT-2103 to that of female patients randomized to paclitaxel.

• Country None
• organs None
• Specialty None

Cell Therapeutics PIX301 : Essai de phase 3 randomisé comparant l’efficacité du pixantrone à différentes mono-chimiothérapies chez des patients ayant un lymphome. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] Pixantrone (BBR 2778) versus other chemotherapeutic agents for third-line single agent treatment of patients with relapsed aggressive non-hodgkin's lymphoma: a randomized, controlled, phase III compar...

• Country France
• organs Lymphomes non hodgkinien
• Specialty Chimiothérapie, Thérapies Ciblées

Phase II open label study of CT-2106 as a single agent in patients with advanced metastatic ovarian cancer who have failed one prior platinum and taxane based regimen To determine the overall response rate (complete plus partial response) of CT-2106 in patients with advanced ovarian cancer who have failed one prior platinum and taxane based regimen.

• Country None
• organs None
• Specialty None

Biogen 307940/106-20 : Essai de phase 3 randomisé évaluant l’efficacité et la tolérance d’un traitement d’entretien par ibritumomab tiuxétan chez des patients ayant un lymphome en rémission complète après une chimiothérapie de type R-CHOP. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de l’essai est d’évaluer l’efficacité et la tolérance d’un traitement d’entretien par ibritumomab tiuxétan chez des patients ayant un lymphome. Après avoir été traités par R-CHOP, les pati...

• Country France
• organs Lymphomes non hodgkinien
• Specialty Thérapies Ciblées, Gériatrie

Cell Therapeutics RAPID : Essai de phase 2 comparant l’efficacité de 2 chimiothérapies, de type R-CHOP (rituximab, cyclophosphamide, doxorubicine, vincristine et prednisone) et R-CPOP (rituximab, cyclophosphamide, pixantrone, vincristine et prednisone) chez des patients ayant un lymphome. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] Cyclophosphamide, doxorubicin, vincristine, prednisone plus rituximab (CHOP-R) and cyclophosphamide, pixantrone, vincristine, prednisone plus rituximab (CPOP-R) in patients with diffuse large-b-cell l...

• Country France
• organs Lymphomes non hodgkinien
• Specialty Chimiothérapie, Thérapies Ciblées

A study comparing current standard therapies with pacritinib taken by mouth for the treatment of myelofibrosis (either diagnosed alone or after polycythemia vera or essential thrombocytopenia) in patients with a low platelet count The primary objective is to compare the efficacy of two dose-schedule arm(s) of pacritinib (pooled once daily [QD] and twice-daily [BID] dosing arms) with that of best available therapy (BAT) in patie...

• Country None
• organs None
• Specialty None